Evidence map›Paper›PMID 30279379›Full record

ArticleInternational journal of molecular sciences2018

SRSF3, a Splicer of the PKM Gene, Regulates Cell Growth and Maintenance of Cancer-Specific Energy Metabolism in Colon Cancer Cells.

Yuki Kuranaga, Nobuhiko Sugito, Haruka Shinohara, Takuya Tsujino, Kohei Taniguchi, Kazumasa Komura, Yuko Ito, Tomoyoshi Soga, Yukihiro Akao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Splicing to orchestrate cell fate.Molecular therapy. Nucleic acids · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yuki KuranagaUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagito, Gifu, Gifu 501-1193, Japan. v3501001@edu.gifu-u.ac.jp.ORCID 0000-0001-7418-6520
Nobuhiko SugitoUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagito, Gifu, Gifu 501-1193, Japan. v3501002@edu.gifu-u.ac.jp.
Haruka ShinoharaUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagito, Gifu, Gifu 501-1193, Japan. harukashinohara313@gmail.com.
Takuya TsujinoDepartment of Urology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. uro061@osaka-med.ac.jp.
Kohei TaniguchiDepartment of General and Gastroenterological Surgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. sur144@osaka-med.ac.jp.ORCID 0000-0003-0648-1370
Kazumasa KomuraDepartment of Urology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. uro051@osaka-med.ac.jp.
Yuko ItoDepartment of Anatomy and Cell Biology, Division of Life Sciences, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. an1006@osaka-med.ac.jp.
Tomoyoshi SogaInstitute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata 997-0017, Japan. soga@sfc.keio.ac.jp.
Yukihiro AkaoUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagito, Gifu, Gifu 501-1193, Japan. yakao@gifu-u.ac.jp.
Gifu University · JPOsaka Medical and Pharmaceutical University · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serine and arginine rich splicing factor 3 (SRSF3), an SR-rich family protein, has an oncogenic function in various kinds of cancer. However, the detailed mechanism of the function had not been previously clarified. Here, we showed that the SRSF3 splicer regulated the expression profile of the pyruvate kinase, which is one of the rate-limiting enzymes in glycolysis. Most cancer cells express pyruvate kinase muscle 2 (PKM2) dominantly to maintain a glycolysis-dominant energy metabolism. Overexpression of SRSF3, as well as that of another splicer, polypyrimidine tract binding protein 1 (PTBP1) and heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1), in clinical cancer samples supported the notion that these proteins decreased the Pyruvate kinase muscle 1 (PKM1)/PKM2 ratio, which positively contributed to a glycolysis-dominant metabolism. The silencing of

Indexed as

Energy MetabolismAdultAgedAged, 80 and overAnimalsAutophagyCarcinogenesisCell Line, TumorCell ProliferationColonic NeoplasmsFemaleGene SilencingHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear RibonucleoproteinsHumansIsoenzymesHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear RibonucleoproteinsIsoenzymesPolypyrimidine Tract-Binding ProteinPTBP1 protein, humanPyruvate KinaseReactive Oxygen SpeciesRNA, MessengerSerine-Arginine Splicing FactorsSRSF3 protein, humanalternative splicingenergy metabolismoncogenes

Identifiers

PMID30279379
PMCPMC6213643
OpenAlexW2894653784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.